CClinicalTrials.gg
WithdrawnNCT04298814Updated Jul 20, 2020

Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia

An observational study in COVID-19 and Endotracheal Intubation, sponsored by Tongji Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-07-20.

Sponsored by Tongji Hospital · Observational

Why this study was withdrawn
It was repeated with other studies in the same department
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To analyze the intubation with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients with severe covid-19 pneumonia.

Read the detailed description

To analyze the intubation time, intubation condition, intubation process, intubation times and success rate of patients with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, the degree of respiratory improvement and survival rate of patients, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients with severe covid-19 pneumonia.

02

Conditions studied

  • COVID-19
  • Endotracheal Intubation
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 373 studies on the registry; 204 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Severe and critical patients with covid-19 pneumonia in urgent need of tracheal intubation

Inclusion criteria

  • Wuhan residents;
  • novel coronavirus pneumonia was found to be characterized by fever and cough. Laboratory tests revealed leukocyte or lymphocyte decrease, chest CT examination showed viral pneumonia changes, and was diagnosed as COVID-19 pneumonia according to the national health and Health Committee's new coronavirus pneumonia diagnosis and treatment plan (trial version fifth Revision).
  • Severe and critical patients with covid-19 pneumonia in urgent need of tracheal intubation;
  • Sign informed consent.

Exclusion criteria

Exclusion Criteria:

  • Suspected patients with covid-19 pneumonia;
  • Patients who need emergency endotracheal intubation due to other causes of respiratory failure;
  • The family refused to sign the informed consent.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • Othersevere covid-19 pneumonia with ET

    severe covid-19 pneumonia undergoing endotracheal intubation

06

What researchers measure

Primary outcomes

  1. Success rate of intubation

    The data of Success rate of intubation with severe COVID-19 pneumonia patients

    Time frame: the time span between 1hour before intubation and 24h after intubation

  2. Infection rate of Anesthesiologist

    Infection rate of Anesthesiologist who performed the endotracheal intubation for severe COVID-19 pneumonia patients

    Time frame: the time span between 1hour before intubation and 14days after intubation

Secondary outcomes

  1. Extubation time

    Extubation time of intubated severe COVID-19 pneumonia patients

    Time frame: the time span between 1hour before intubation and 30days after intubation

07

Study locations

1 site
  • Tongji Hospital
    Wuhan, Hubei 430000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04298814
Lead sponsor
Tongji Hospital
Responsible party
aijun xu (associate professor, Tongji Hospital) — Principal investigator
First posted
Mar 6, 2020
Start date
Aug 7, 2020 (estimated)
Primary completion
Dec 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Jul 20, 2020

Study contacts

Aijun XU, Dr.
principal investigator · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion